Demis Hassabis just raised $5 BILLION to accelerate AI-powered drug discovery. His company, Isomorphic Labs, has an extraordinarily ambitious mission: Solve All Disease. And some of the world's biggest investors are betting that artificial intelligence could fundamentally change how medicines are discovered and developed. On November 17, 2026, Isomorphic Labs announced a $5 billion Series C funding round. THE INVESTORS • Sequoia Capital • Greenoaks • Andreessen Horowitz (a16z) • Alphabet • Thrive Capital • MGX • GV and CapitalG • Temasek • UK Sovereign AI Fund The round was co-led by Sequoia and Greenoaks. WHAT IS ISOMORPHIC LABS? Founded in 2021 as a company emerging from Google DeepMind, Isomorphic Labs is led by Demis Hassabis, the Nobel Prize-winning AI researcher behind DeepMind and AlphaFold. The company is attempting to reinvent drug discovery using artificial intelligence. Its central technology is IsoDDE, the Isomorphic Labs Drug Design Engine. Instead of relying exclusively on traditional laboratory experimentation, IsoDDE uses predictive and generative AI models to explore enormous numbers of potential drug molecules. The goal is to identify promising candidates, understand their biological interactions, predict their properties, and refine their molecular structures before expensive laboratory testing. WHAT WILL THE $5 BILLION FUND? • Scaling the IsoDDE AI drug design engine. • Developing more advanced foundation models for biology and chemistry. • Expanding AI-designed therapeutic candidates. • Advancing internal drug programs toward human clinical trials. • Building infrastructure for AI-driven biomedical research and drug development. • Expanding partnerships with pharmaceutical companies and scientific institutions. Isomorphic Labs already collaborates with major pharmaceutical companies, including Eli Lilly, Novartis, and Johnson & Johnson. The company reports promising preclinical results in oncology and immunology. BUT HERE'S THE IMPORTANT DISTINCTION. AI-designed molecules are not the same as approved medicines. Even when artificial intelligence identifies promising drug candidates, they still need laboratory validation, clinical trials, safety testing, and regulatory approval. Isomorphic Labs has not yet demonstrated that its technology can cure all diseases or deliver a clinically approved AI-designed medicine. And $5 billion doesn't change those scientific requirements. SO WHY IS THIS SUCH A BIG DEAL? Because we're watching frontier AI move beyond chatbots, coding agents, and generative media. Into biology. Into chemistry. Into the development of actual medicines. If AI can significantly improve how scientists design and evaluate new molecules, it could eventually change the economics and speed of pharmaceutical research. And that might become one of the most important applications of artificial intelligence. Isomorphic Labs isn't promising a universal cure for cancer tomorrow. But investors are committing billions to the possibility that AI can help discover treatments that were previously too difficult, expensive, or complex to develop. Which raises the obvious question. How long until we see the first major breakthrough from this new generation of AI-designed medicines? Official Isomorphic Labs announcement: https://www.isomorphiclabs.com/articles/isomorphic-labs-announces-series-c-investment-round Isomorphic Labs: https://www.isomorphiclabs.com/ Isomorphic Labs Drug Design Engine: https://www.isomorphiclabs.com/our-tech What do you think? Could AI help make previously untreatable diseases treatable within the next decade? #IsomorphicLabs #DemisHassabis #AIDrugDiscovery